Expression data of control, doxorubicin and/or Y27632 treated HeLa cells

In the treatment of cancer with chemotherapeutics, it has been observed that a significant amount of cancer cells turn into senescent cells. These senescent cells secrete several factors in their microenvironment called SASP. Therefore, recently, to develop the senolytic and/or senomorphic drugs, targeting the senescent cells gains importance as a new strategy for preventing the damage that senescent cancer cells cause. In the current work, we evaluated whether Rho/Rho kinase pathway has a potential to be used as a target pathway for the development of senolytic and/or senomorphic drugs, in doxorubicin-induced senescent cancer cell lines. We performed a whole-genome microarray analysis to determine how the expressions of SASP factors change in senescent cells and whether ROCK inhibition also causes changes in the expression of these factors. HeLa cells were incubated for 6 days without treatment (group K, n=3), or treated with 300 nM doxorubicin for 72 h and then incubated for 72 hours without treatment (group D, n=3), or treated with 300 nM doxorubicin for 72 h and then treated with 10μM Y27632 ( a Rho kinase inhibitor) for 72h (group D+Ys, n=3), or pretreated with 10μM Y27632 ( a Rho kinase inhibitor, 30 min) and treated with 300 nM doxorubicin for 72 h, and then incubated for 72 hours without treatment (group D+Y, n=3),or incubated for 72 h without treatment and then treated with 10μM Y27632 ( a Rho kinase inhibitor) for 72 h (group Y, n=3). Human Gene 1.0 ST Array chips were used for gene expression analyses. The cell intensity, CEL, files were analyzed using Affymetrix Expression Console Software 1.4.1.46 at gene level with RMA (Robust Multiarray Average) normalization algorithm. Differentially expressed genes were identified using BRB-ArrayTools version 4.6.0.